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ORIGINAL ARTICLEPDE4 Inhibition as Potential Treatment
of Epidermolysis Bullosa Acquisita
Hiroshi Koga1,7, Andreas Recke1, Gestur Vidarsson2, Hendri H. Pas3, Marcel F. Jonkman3,
Takashi Hashimoto4, Anika Kasprick1, Saeedeh Ghorbanalipoor1, Hermann Tenor5,
Detlef Zillikens1,6 and Ralf J. Ludwig1,6Pemphigoid diseases such as epidermolysis bullosa acquisita (EBA) may be difficult to treat. In pemphigoid
diseases, mucocutaneous blistering is caused by autoantibodies to hemidesmosomal antigens; in EBA the
autoantigen is type VII collagen. Despite growing insights into pemphigoid disease pathogenesis, corticoste-
roids are still a mainstay of treatment. In experimental EBA, myeloid cell activation is a key event leading to
blistering. Activation of these cells depends on phosphodiesterase (PDE) 4. We therefore evaluated the
potential for PDE4 inhibition in EBA: PDE4 was highly expressed in inflammatory cells and in the epidermis of
patients compared with healthy skin samples. PDE4 inhibitors rolipram, roflumilast, and roflumilast N-oxide
prevented the release of immune complex-induced reactive oxygen species from polymorphonuclear leuko-
cytes and separation of the dermal-epidermal junction of skin incubated with antibodies to collagen type VII
and polymorphonuclear leukocytes. The PDE4 inhibitors also impaired CD62L shedding and decreased CD11b
expression on immune complex-stimulated polymorphonuclear leukocytes. For in vivo validation, experi-
mental EBA was induced in mice by transfer of anti-collagen type VII IgG or immunization with collagen type
VII. Roflumilast dose-dependently reduced blistering in antibody transfer-induced EBA and also hindered
disease progression in immunization-induced EBA. PDE4 inhibition emerges as a new treatment modality for
EBA and possibly other neutrophil-driven pemphigoid diseases.
Journal of Investigative Dermatology (2016) 136, 2211e2220; doi:10.1016/j.jid.2016.06.619INTRODUCTION
Pemphigoid diseases (PDs) are prototypical organ-specific
autoimmune diseases caused by autoantibodies that are
directed against proteins of basement membrane zone, such
as type XVII collagen, type VII collagen (COL7), or laminin
332. Mucocutaneous blistering is the clinical hallmark of PD,
but they are quite heterogeneous with respect to their overall
clinical presentation, target antigens, and autoantibody iso-
type (Schmidt and Zillikens, 2013). The PD epidermolysis
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ª 2016 The Authors. Published by Elsevier, Inc. on behalf of the Society for Invautoantibodies against COL7 (Woodley et al., 1988). EBA
may present as either classic, mechanobullous EBA with
tense blisters and skin fragility preferentially localized to the
extensor skin surfaces at trauma-prone areas or, more
commonly, as an inflammatory skin disease mimicking other
PDs such as bullous pemphigoid or mucous membrane
pemphigoid (Buijsrogge et al., 2011; Gupta et al., 2012;
Ludwig, 2013a; Zumelzu et al., 2011). Predominantly, the
latter variant can be duplicated in mice by either antibody
transfer or immunization.
Use of these animal models has greatly enhanced our
understanding of the inflammatory type of EBA pathogenesis
(Ludwig et al., 2013b): in genetically predisposed individuals
(Gammon et al., 1988; Ludwig et al., 2012; Zumelzu et al.,
2011), autoantibodies to COL7 are generated by a
T-celledependent B-cell response (Iwata et al., 2013).
Depletion of neutrophils impairs the formation of COL7-
specific autoantibodies (Samavedam et al., 2014). Once
formed, the half-life and biodistribution of the anti-COL7
IgG, which can be found in 54% of EBA patients
(Buijsrogge et al., 2011), is controlled by the neonatal Fc
receptor (Sesarman et al., 2008). Circulating anti-COL7
autoantibodies rapidly bind to their target antigen, mainly
expressed in the skin (Ishii et al., 2011), which leads to the
formation of skin-bound immune complexes (ICs). Through
partially understood mechanisms involving complement
activation and cytokine release (Ludwig et al., 2013b), an
ICAM-1/CD18edependent extravasation of myeloid cells
into the skin is induced (Chiriac et al., 2007; Sadeghi et al.,
2015b). After Fc gamma receptor IV-dependent binding to
the IC (Kasperkiewicz et al., 2012) and an immunoreceptorestigative Dermatology. www.jidonline.org 2211
H Koga et al.
PDE4 in EBA
2212tyrosine-based activation motif (ITAM)edependent signaling
cascade (Hellberg et al., 2013; Futosi et al., 2013; Kulkarni
et al., 2011; Nimmerjahn et al., 2005), myeloid cells
release reactive oxygen species (ROS) and proteases, which
ultimately causes inflammation and blistering (Chiriac et al.,
2007; Sitaru et al., 2002a).
Regarding intracellular signaling pathways in EBA, rela-
tively little is known: IC-induced activation of myeloid cells
and neutrophils (in the context of EBA) requires phosphoi-
nositide 3-kinase-b (PI3Kb), protein kinase B (Akt),
extracellular signal-related kinase (ERK), p38, retinoic acid
receptor-related orphan receptorealpha (i.e., RORa) and Src
family kinases (Hellberg et al., 2013; Kovacs et al., 2014;
Kulkarni et al., 2011; Sadeghi et al., 2015a). In addition,
increased phosphorylation of Akt and ERK 1/2 has been
noted in bullous pemphigoid patient skin samples (Hellberg
et al., 2013). More recently, inflammation-resolving mecha-
nisms (i.e., modulators of wound healing), involving flightless
I (Kopecki et al., 2013) have been identified. Therefore,
myeloid cells (i.e., neutrophils) are key effector cells in EBA,
acting by contributing to the generation of autoantibodies
and by being essential for the induction of cutaneous
inflammation and blistering. Despite these insights into EBA
pathogenesis, corticosteroids are still a mainstay of treatment.
In addition to a relatively poor response to treatment (Kim
et al., 2011), adverse drug reactions contribute to the high
morbidity of EBA patients. Hence, there is a significant unmet
medical need for the development of new therapeutics for
EBA and other PDs (Ludwig et al., 2013b).
In parallel to the growing understanding of EBA patho-
genesis, small molecules modulating signal transduction
have been developed to treat cancer and chronic inflamma-
tory diseases (Ghoreschi and Gadina, 2014). The approval of
the phosphodiesterase 4 (PDE4) inhibitor apremilast for the
treatment of psoriasis (Papp et al., 2012; Papp et al., 2015)
underscores the potential of targeting these pathways for the
treatment of chronic inflammatory diseases. In general, PDE4
supports proinflammatory effects by degrading cAMP in
inflammatory cells, smooth muscle cells, endothelial cells,
and keratinocytes (Chujor et al., 1998; Torphy, 1998). Inhi-
bition of PDE4 induces accumulation of the intracellular
second messenger cAMP and activates protein kinase A,
followed by phosphorylation of the transcription factor
cAMP-response element binding protein, resulting in a
decrease of proinflammatory mediators, including tumor
necrosis factor-a, IL-17, and IFN-g (Jimenez et al., 2001; Liu
et al., 2000; Sheibanie et al., 2004). At the same time, inhi-
bition of PDE4 increases the expression of anti-inflammatory
mediators, such as IL-10 (Oger et al., 2005). Furthermore, the
PDE4 inhibitors rolipram (ROL) and cilomilast inhibit pro-
matrix metalloproteinase-9 activity (Oger et al., 2005), and
roflumilast (ROF) hinders activation of NF-kB and phos-
phorylation of mitogen-activated protein kinase (MAPK),
including c-Jun N-terminal kinase and p38MAPK, in murine
macrophages (Kwak et al., 2005). In murine neutrophils, ROL
has been reported to block activation of Akt and NF-kB
(Sousa et al., 2010).
Hence, we hypothesized that PDE4 inhibition impairs
IC-induced neutrophil activation, thus rendering it a potential
target for the treatment of EBA and other PDs. OurJournal of Investigative Dermatology (2016), Volume 136assumption was based on the facts that (i) PDE4 is the key
enzyme accounting for cAMP degradation in neutrophils
(Schudt et al., 1991) and (ii) PDE4 inhibitors are highly
effective to curb neutrophil functions (Sousa et al., 2010). In
this study, we challenged this assumption and evaluated the
impact of PDE4 inhibitors on key pathogenic steps in EBA
in vitro. We also evaluated the effects of PDE4 inhibition
on preclinical models of the disease.
RESULTS
Increased expression of PDE4 in EBA patient skin
We first compared the PDE4 expression of inflammatory-type
EBA skin at lesional sites with normal human skin. We
detected little PDE4 expression in normal human skin (n¼ 4).
In contrast, a strong signal for PDE4 was noted in the
epidermis and/or dermis in all four EBA-patient specimens
(Figure 1a). Quantification of the PDE4 staining intensity
confirmed the visual assessment: an increased florescence
intensity in both epidermis and dermis in EBA patients
compared with control skin (Figure 1b and c). We also
determined the PDE4 expression in skin specimens from
patients with the mechanobullous type of EBA. We observed
no difference in PDE4 expression compared with healthy skin
(data not shown).
PDE4 inhibition reduces reactive oxygen species (ROS)
release from polymorphonuclear leukocytes (PMNs)
activated by COL7/anti-COL7 IgG ICs
Having detected increased PDE4 expression at the site of
inflammation, we next addressed the functional relevance of
this finding. We focused on the dermal PDE4 expression (i.e.,
most likely corresponding to leukocytes), because myeloid
cells (PMNs) are required to induce cutaneous inflammation
and blistering in experimental models of EBA, whereas the
contribution of keratinocytes to EBA pathogenesis remains to
be elucidated. ROS release from activated PMN is a key
effector in the pathogenesis of EBA (Ludwig, 2013a). We
therefore evaluated the impact of PDE4 inhibitors ROF, ROL,
and roflumilast N-oxide (RNO) on IC-induced ROS release
from PMN. As previously reported (Recke et al., 2015), the
addition of PMN to IC of COL7 protein and anti-COL7 IgG1
leads to their activation, as detected by ROS release. All
tested PDE4 inhibitors reduced the IC-induced ROS release
from PMN in a dose-dependent manner (Figure 2a). The
observed changes in IC-induced ROS release were achieved
at nontoxic concentrations of all compounds as judged
by annexin V/propidium iodide staining (see Supplementary
Figure S1 online).
PDE4 inhibition reduces autoantibody-induced,
PMN-dependent separation of the dermal-epidermal
junction in cryosections of human skin
Incubation of cryosections of normal human skin with anti-
COL7 IgG induces PMN-dependent separation of the
dermal-epidermal junction, reflecting their activation by the
IC located at the dermal-epidermal junction (Ludwig, 2013a).
Here, cryosections of human skin were incubated with rabbit
anti-human COL7 serum or normal rabbit serum, followed by
the addition of PMN obtained from healthy volunteers. As
reported earlier (Sitaru et al., 2002a), cryosections incubated
with anti-human COL7 serum showed separation of the
Figure 1. Increased expression of
PDE4 in the skin of EBA patients. (a)
PDE4 expression (green) was
evaluated in EBA patient skin (n ¼ 4)
and healthy controls (n ¼ 4). Nuclei
were counterstained with DAPI (blue).
Here, all stained EBA patient samples
and three of four controls, as well as
an isotype control staining, are shown.
Scale bar ¼ 20 mm. To quantify the
expression of PDE4, (b) the MFI
(arbitrary units) of the epidermis and
the number of PDE4-positive cells in
the dermis were analyzed. Both MFI in
the epidermis and (c) PDE4þ cells
in the dermis were significantly
increased relative to normal skin (two-
tailed t test). MFIs and number of
PDE4-positive cells were analyzed by
Image J (National Institutes of Health,
Bethesda, MD) and BZ-II analyzer
(Keyence, Frankfurt, Germany). EBA,
epidermolysis bullosa acquisita; MFI,
mean fluorescence intensity; PDE4,
phosphodiesterase 4.
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PDE4 in EBAdermal-epidermal junction, which was almost completely
absent in sections incubated with normal rabbit serum.
Addition of PDE4 inhibitors dose-dependently impaired
autoantibody-induced, PMN-dependent separation of the
dermal-epidermal junction: ROL prevented separation of the
dermal-epidermal junction at 100 nmol/L, whereas ROF and
RNO blocked separation of the dermal-epidermal junction
at concentrations as low as 10 nmol/L (Figure 2b).
PDE4 inhibitors prevent specific, but not all, IC-induced
neutrophil changes in surface molecule (CD11b, CD62L,
and CD66b) expression
In addition to ROS release, decreased L-selectin (CD62L)
expression and an increase in CD11b and CD66b are hall-
marks of neutrophil activation (Faurschou and Borregaard,
2003). Therefore, we next analyzed the expression of these
markers on PMN stimulated by COL7-IC. ROF and RNO
slightly but significantly reduced CD11b expression and
impaired shedding of CD62L. In contrast, ROL did not reduce
either, although similar tendencies were observed (Figure 2c
and d). CD66b expression did not change in the presence
of any of the three PDE4 inhibitors (Figure 2e).
The PDE4 inhibitor roflumilast impairs disease induction in
antibody transfer-induced EBA
The transfer of anti-COL7 IgG into mice induces experi-
mental EBA, mostly resembling the inflammatory variant of
the disease (Iwata et al., 2015a). Here, we confirmed these
observations: mice were injected with anti-COL7 IgG and
treated with vehicle (control treatment for ROF); they
developed severe erosions, crusts, and alopecia on the skin.Preventive and continuous treatment with 5 mg/kg of ROF
led to slightly but significantly milder symptoms, whereas
1 mg/kg had no effect (Figure 3aec). The degree of dermal
leukocyte infiltration at day 12 of the experiment was eval-
uated using hematoxylin and eosin-stained slides. Here, mice
treated with 5 mg/kg of ROF presented with significantly
milder inflammatory cell infiltration compared with either
vehicle treatment alone or 1 mg/kg of ROF (Figure 3d). In the
next set of experiments, we compared the effect of ROF with
corticosteroid (methylprednisolone 20 mg/kg) treatment in
this model, and treated mice simultaneously with both drugs
to test for potential synergistic effects, which were reported in
other models (Ogawa et al., 2002; Milara et al., 2014). In line
with our previous results, treatment with ROF impaired dis-
ease induction. Compared with methylprednisolone, both
treatments were equally effective. The combined treatment
with corticosteroid and ROF did not, however, further
decrease disease induction and thus did not point toward
synergistic effects (see Supplementary Figure S2 online).
The PDE4 inhibitor ROF suppresses disease progression in
mice with established immunization-induced EBA
To test if ROF treatment also affects disease severity in mice
with already established immunization-induced EBA (Iwata
et al., 2013), mice with 2% or more of their body surface
area affected by skin lesions were randomly allocated to the
vehicle or ROF (5 mg/kg/day, orally) treatment groups. In
vehicle-treated mice, the magnitude of skin blistering further
increased during the 6-week study period, reaching a









































































































































































































































































































































































Figure 2. Suppression of in vitro and ex vivo PMN activation by PDE4 inhibitors. (a) Freshly isolated human PMN (n ¼ 5) were activated by an immune
complex (COL7/anti-COL7) in the presence of various concentrations of rolipram (ROL), roflumilast (ROF) or roflumilast-N-oxide (RNO). Their reactive oxygen
species (ROS) release was measured over time. The cumulative ROS release, expressed as area under the curve of ROS production for 1 hour per sample, was
related to the ROS release of vehicle-treated, immune complex-activated PMNs (DMSO). All PDE4 inhibitors dose-dependently reduced the immune complex-
induced ROS release from PMN. (b) PMN activation can also be assessed by incubation on tissue-bound immune complexes (generated by exposing
cryosections of human skin with anti-COL7 IgG), leading to separation of the dermal-epidermal junction (arrow). Consistent with the ROS release data, addition
of PDE4 inhibitors dose-dependently impaired the induction of separation of the dermal-epidermal junction. The lower three graphs represent the separation of
the dermal-epidermal junction in PDE4 inhibitor-treated samples compared with solvent control. Because of the high variability among different donors, data
were normalized to the positive control (antibodies, PMN, and solvent). Scale bar ¼ 100 mm. (c) PMN (n ¼ 8) were incubated without (cells only) or with
immune complexes (IC) and solvent (DMSO) in the absence or presence of PDE4 inhibitors. Stimulation with fMLP served as the control of PMN activation.
Obtained data were normalized to the solvent group (DMSO). PDE4 inhibitors had only marginal, albeit statistically significant, effects on CD11b expression
(expressed as relative changes of the percentage of cells expressing CD11b), whereas (d) a greater effect was noted regarding CD62L shedding, and (e) no effect
was observed on the degranulation marker CD66b. Hence, PDE4 inhibition seems to preferentially inhibit ROS release and shedding of L-selectin on immune
complex-activated PMN. *P< 0.05, **P< 0.01 (one-way analysis of variance). COL7, collagen type VII; IC, immune complex; NRS, normal rabbit serum; PDE4,
phosphodiesterase 4; PMN, polymorphonuclear leukocyte; rel, relative; RLU, relative light unit; RNO, roflumilast N-oxide; ROF, roflumilast; ROL, rolipram;
ROS, reactive oxygen species.
H Koga et al.
PDE4 in EBA
2214clinical disease activity gradually declined but was still
almost 2-fold higher at the end of the study period than at
time of allocation. Compared with vehicle-treated animals,
the percentage of the affected body surface area in ROF-
treated mice was significantly lower at 2 and 3 weeks after
treatment initiation (Figure 4a and b). In each group,
percentage of affected body area after 3 weeks gradually
decreased. Overall disease activity, measured as area under
the curve, was derived from the disease progression of
individual mice in each treatment group and was also
significantly lower in mice treated with ROF than in the
vehicle-treated animals (Figure 4c). To investigate possible
effects of ROF treatment on antigen-specific antibody
production, we next analyzed the levels of circulating anti-
vWFA2 IgG. However, we did not find significant differ-
ences between the two groups (data not shown). To test for
the potential cytotoxicity of ROF in vivo, differential bloodJournal of Investigative Dermatology (2016), Volume 136counts of the mice at the final day (6 weeks) were made. No
significant differences in the peripheral blood counts were
noted among the groups (see Supplementary Table S1
online).
PMN from mice with immunization-induced EBA treated
with ROF show impaired neutrophil activation
So far, we have shown that PDE4 inhibitors reduced ROS
production from PMNs in vitro (Figure 2a) and that the
treatment of mice with the PDE4 inhibitor ROF impairs dis-
ease induction and progression in experimental EBA
(Figures 3 and 4). To link these findings (and to possibly link
the observed therapeutic effects of ROF to inhibition of
neutrophil function in vivo), PMNs from vehicle-treated and
ROF-treated (5 mg/kg) mice obtained at the end of the
treatment period in the experiments with immunization-



























































Figure 3. ROF prevents induction of subepidermal blistering in antibody transfer-induced EBA in mice. EBA was induced in C57BL/6J mice by anti-COL7 IgG
transfer, and mice were treated with ROF at varying concentrations or vehicle (n ¼ 15e16 mice/group). (a) Representative clinical pictures of the mice in the
indicated treatment groups on day 12. (b) Indicates the percentage of affected body surface area in the treatment groups (*P < 0.05 for 5 mg/kg ROF vs. solvent,
two-way analysis of variance, considering day and treatment type). (c) Cumulative clinical disease manifestation, expressed as area under the curve calculated
from panel b. Comparison of the groups was performed using one-way analysis of variance with a Bonferroni t test as a posttest. (d) Hematoxylin and eosin-
stained sections from ears (three fields, 15e16 mice/group) were semiquantitatively scored by three observers blinded to the treatment group. The scores ranged
from 0 to 5, corresponding to degree of dermal leukocyte infiltration. The data are presented as the median (line), 25th/75th percentiles (boxes), and 5th/95th
percentiles (error bars). Comparison of the amounts of the groups was performed using one-way analysis of variance with a Bonferroni t test as a posttest. AUC,
area under the curve; COL7, collagen type VII; EBA, epidermolysis bullosa acquisita; HE, hematoxylin and eosin; ROF, roflumilast.
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PDE4 in EBAphorbol 12-myristate 13-acetate (PMA). The purified PMNs
from both groups produced ROS when activated with PMA.
After PMA stimulation, the PMNs from the ROF-treated mice
produced less ROS than the vehicle-treated mice (Figure 5).
DISCUSSION
Collectively, we show the inhibitory properties of ROF on
IC-activated PMN in vitro and ex vivo. Furthermore, we
describe how PDE4 inhibition slows the onset of blistering in
antibody transfer-induced murine EBA, an antibody-induced
and myeloid cell/neutrophil-mediated disease. Even more
strikingly, we found this drug to prevent further disease pro-
gression in mice with already established EBA. The reduced
PMN response from ROF-treated mice to in vitro stimulation
indicates that the observed clinical effects are at least partly
due to inhibition of PMN activation. Other published treat-
ments for experimental EBA, including methylprednisolone,
high doses of intravenous IgG, and soluble CD32, like ROF,
also all impaired disease progression (Hellberg et al., 2013;
Hirose et al., 2015; Iwata et al., 2015b). HSP90 blockade,
the IL-1 receptor antagonist anakinra and dimethyl fumarate
were shown to improve even already established disease
(Kasperkiewicz et al., 2011; Muller et al., 2016; Samavedam
et al., 2013). Thus, the therapeutic efficacy of ROF in
experimental EBA is comparable to those of establishedtreatments in EBA patients, such as systemic corticosteroids
or intravenous IgG (Kim and Kim, 2013).
In the context of EBA, IC-induced ROS release from
neutrophils is triggered by the binding of specific activating
Fc gamma receptors to the tissue-bound antibodies
(Kasperkiewicz et al., 2012; Yu et al., 2010), ultimately
leading to the NCF1-dependent release of ROS (Chiriac et al.,
2007). So far, PI3Kb, ERK2 (MAPK1), p38 (MAPK14), Akt, and
the Src family kinases Hck, Fgr, and Lyn have been shown to
mediate signaling downstream of Fc gamma receptor binding
(Hellberg et al., 2013; Kovacs et al., 2014; Kulkarni et al.,
2011; Sadeghi et al., 2015a). Independent of the EBA
context, downstream meditators such as Ras, Rac, Rho,
protein kinase C, and phospholipase C-gamma (PLCg) have
all been shown to be involved in downstream signaling that
activates Fc gamma receptors (Nimmerjahn and Ravetch,
2008). To obtain insights into the interaction of these mole-
cules, we used the STRING database, allowing the identifi-
cation of functional interactions between proteins (Jensen
et al., 2009). With the exception of Rora, all entered genes
were linked into a complex network (see Supplementary
Figure S3 online). Fcgr4 is directly linked to Hck, which
then evolves into a complex and interacting network,
resulting in predominant activation of Prkca, Rac1, Akt1,

































Figure 4. ROF hinders disease
progression in mice already clinically
manifesting immunization-induced
EBA. EBAwas induced in B6.SJL-H2s
(B6.s) mice by single immunization.
After immunization, mice were
allocated to treatment groupswhen 2%
or more of their body surface area
was affected by skin lesions. (a)
Representative clinical pictures ofmice
in the indicated treatment groups at 3
weeks of treatment. (b) Affected body
surface area in ROF-treated (n ¼ 9) or
vehicle-treated (n ¼ 9) animals during
the 6-week treatment period (*P <
0.05, two-way analysis of variance,
taking week and treatment type into
consideration). (c) AUC of percentage
affected body area until 6 weeks in
each group (Mann-Whitney Rank Sum
Test). AUC, area under the curve; rel,
relative; ROF, roflumilast; w, weeks.
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2216Based on the incomplete inhibition of ROS release from
IC-activated neutrophils using inhibitors of Akt, p38, or
ERK (Hellberg et al., 2013), we assume that additional
pathways can lead to the activation of NCF1. PDE4, espe-
cially PDE4B, is linked to MAPK1 and -14, which are linked
to NCF1 (see Supplementary Figure S3). The interactions
shown in Supplementary Figure S3 are based on the pre-
dictions of the STRING database and need to be experi-
mentally validated in the context of EBA. We recently
showed the crucial roles of both MAPKs in IC-induced ROS
release from neutrophils (Hellberg et al., 2013), indicating
that the interaction of these two MAPKs with PDE4 may be
crucial for the release of ROS from IC-activated myeloid
cells. This assumption is supported by the observation of a
decreased signal intensity of MAPK in stimulated airway
epithelial cells treated with PDE4 inhibitors (Victoni et al.,
2014).
In addition to insights into downstream signaling that
activates Fc gamma receptors and into the pathogenesis of
blistering in EBA (Iwata et al., 2015c; Kasperkiewicz et al.,
2016), our results are also of clinical relevance. First, the
primary treatment of patients with PD, including EBA, is
topical or systemic corticosteroid treatment (Joly et al., 2002;Figure 5. Reduced release of ROS in
PMN isolated from ROF-treated mice.
Murine PMN were isolated from the
bone marrow of vehicle-treated (n¼4)
and ROF-treated mice (5mg/kg/day
p.o.; n ¼ 5) at 6 week. (a) PMNs were
stimulated with PMA, and subsequent
ROS production was monitored. (b)
AUC of ROS production from vehicle
treated- and ROF-treated mice
(P ¼ 0.0465, one-tailed t test). AUC,
area under the curve; PMA, phorbol
12-myristate 13-acetate; PMN,
polymorphonuclear leukocyte; RLU,
relative light unit; ROF, roflumilast;
ROS, reactive oxygen species.
Journal of Investigative Dermatology (2016), Volume 136Kim et al., 2011). In accordance with this clinical practice,
systemic corticosteroids are effective in mice with already
established immunization-induced EBA (Hirose et al., 2015).
In patients, the drawbacks of continued corticosteroid treat-
ment include frequent relapses after withdrawal in bullous
pemphigoid (Joly et al., 2009), insufficient efficacy in EBA
and mucous membrane pemphigoid (Kim et al., 2011) and
treatment-associated adverse drug reactions in both disorders
(Buchman, 2001). The combination of corticosteroids with
PDE4 inhibitors enhanced glucocorticoid sensitivity in
human acute lymphoblastic leukemia and in human acute
lymphoblastic leukemia cells (Ogawa et al., 2002), pointing
to the synergistic effects of the two drugs. Similar observa-
tions were made in neutrophils from patients with chronic
obstructive pulmonary disease. Here, the combination of
RNO and dexamethasone showed additive/synergistic ef-
fects, which were consistent with the reversal of
corticosteroid-resistant molecular markers by RNO (Milara
et al., 2014). In contrast to these observations, the combi-
nation of both compounds did not show synergistic effects in
our preclinical EBA mouse model. However, comparing the
efficacy of ROF and high doses of systemic corticosteroids
head to head in this model showed that both drugs are
H Koga et al.
PDE4 in EBAequally effective in slowing down disease onset. This and the
good tolerance of PDE4 inhibitors in both chronic obstructive
pulmonary disease and psoriasis (Kumar et al., 2013;
Lipworth, 2005) strongly suggests that patients with
corticosteroid-treated EBA may benefit from adjuvant PDE4
inhibition. Recently, apremilast has been licensed for the
treatment of psoriasis (Papp et al., 2012). However, other
PDE4 inhibitors, that is, ROF, have a higher activity
compared with apremilast (Man et al., 2009). We therefore
focused on the effects of ROF, including its metabolites. ROF
is marketed as a treatment for severe chronic obstructive
pulmonary disease to reduce the frequency of exacerbations
(Rabe, 2011; Tashkin, 2014). Neutrophils are a hallmark in
exacerbations, and it is thought that the clinical efficacy of
ROF is partly driven by its effects to inhibit neutrophils
(Grootendorst et al., 2007; Hatzelmann et al., 2010). RNO is
the active metabolite of ROF that largely accounts for overall
PDE4 inhibition, although the clinical efficacy has not been
tested (Bethke et al., 2007; Tenor et al., 2011).
Collectively, we showed that PDE4 inhibitors selectively
affect PMN activation in vitro and ex vivo. We furthermore
showed that PDE4 inhibition impairs both disease manifes-
tation and progression in EBA mouse models and ultimately
link this in vivo inhibitory effect to neutrophil activation.
Hence, adjuvant PDE4 inhibition may be of potential use in
patients with EBA and other forms of PD.
MATERIALS AND METHODS
Studies with human serum, leukocytes, and skin
Enrolled EBA patients (n ¼ 6) fulfilled the following criteria: (i)
presentation with skin lesions resembling EBA, (ii) linear IgG and/or
IgA deposition in direct immunofluorescent microscopy, (iii) pres-
ence of an u-serrated pattern on direct immunofluorescent micro-
scopy and/or detection of autoantibodies against COL7 by Western
blot test in patient serum. Skin biopsy samples from EBA patients
fulfilling these criteria were obtained from the lesional site of
inflammatory type (n ¼ 4) or mechanobullous type (n ¼ 2) for
analysis of PDE4 expression by immunofluorescent microscopy. Skin
specimens from plastic surgery served as a reference. Leukocytes
were collected from healthy blood donors (n ¼ 21). All experiments
using human samples were approved by the local ethics committee
and were performed according to the Declaration of Helsinki. Blood
donors and patients gave their written informed consent before
study participation.
Mice
C57BL/6J (B6) and B6.SJL-H2s (B6.s) mice were obtained from col-
onies held at the animal facility at the University of Lübeck. Animals
were fed acidified drinking water and standard chow ad libitum and
were held on a 12-hour light-dark cycle at the animal facility of the
University of Lübeck. Mice aged 6e10 weeks were used for the
experiments. All clinical examinations, biopsies, and bleedings were
performed under anesthesia with intraperitoneal administration of a
mixture of ketamine (100 mg/g) and xylazine (15 mg/g). The experi-
ments were approved by the Animal Care and Use Committee (Kiel,
Germany) and performed by certified personnel.
Compounds and antibodies
ROL and ROF were purchased from Selleckchem (Munich,
Germany). RNO was purchased from MyBioSource, Inc. (San Diego,
CA). Rabbit anti-PDE4 polyclonal antibody, detecting all knownPDE4 A and D variants with a lower affinity for PDE4B, was
purchased from Abcam (Cambridge, MA), and FITC conjugated
donkey anti-rabbit IgG was purchased from Jackson Immuno
Research (West Grove, PA).
Generation of the vWFA2 recombinant protein and
anti-murine vWFA2 IgG
Recombinant murine vWFA2 of the noncollagenous domain 1 (NC1)
of COL7 (aa 1048e1238 with 5 additional amino acids [GRAMG] at
the N-terminus) were produced as previously described using pro-
karyotic expression (Leineweber et al., 2011). Rabbit anti-murine
vWFA2 IgG was generated as previously described (Iwata et al.,
2015c). IgG from rabbit serum was isolated using Protein G
Sepharose Fast Flow affinity column chromatography (Amersham
Biosciences, Freiburg, Germany) as described (Sitaru et al., 2005).
Reactivity of IgG fractions was analyzed by immunofluorescent
microscopy on murine skin. Concentrations of the purified rabbit
IgG were measured at 280 nm by spectrophotometer.
In vitro PMN activation (ROS release)
Immobilized IC-induced ROS release from PMN was performed as
previously reported (Recke et al., 2014). White microtiter plates
(Greiner BioOne, Frickenhausen, Germany) were coated for 3 hours
with a recombinant protein located within the human non-
collagenous domain of COL7 known as hCOL7EF (Recke et al.,
2014) at 1 mg/well in carbonate buffer at pH 9.6. After washing
with phosphate buffered saline with Tween 20, plates were blocked
with 1% bovine serum albumin in phosphate buffered saline with
Tween 20 overnight at 4 C on a rocking platform. Subsequently,
recombinant chimeric anti-hCOL7EF IgG1 (Recke et al., 2014)
diluted in 1% bovine serum albumin in phosphate buffered saline
with Tween 20 was added and incubated for 1 hour. In parallel,
human PMNs were isolated using PolymorphPrep (Axis-Shield
GmbH, Oslo, Norway) according to the manufacturer’s instructions.
After purification, PMN were resuspended in color-free RPMI 1640
chemiluminescence medium supplemented with 10 mg/ml luminol
(5-amino-2,3-dihydro-1,4-phthalazindione; Roche Diagnostics,
Mannheim, Germany). After preincubation with inhibitors for 15
minutes at room temperature, PMN were added to the plate-fixed IC.
Immediately, chemiluminescencewasmeasured for 60minutes using
a VICTOR 3 reader (PerkinElmer, Waltham, MA). The obtained data
were expressed as relative light units. N-formylmethionyl-leucyl-
phenylalanine (fMLP) at a final concentration of 500 nmol/L was used
as positive control. Each measurement was repeated with PMN from
five donors in duplicate. For a similar assay using murine PMN, the
purification of PMN from femurs 1 hour after final administration of
ROFor vehicle was performed as previously reported (Dorward et al.,
2013). The purified PMNwere incubated with 100 ng/ml of PMA and
measured for 45 minutes, as described for the human PMN.
Determination of separation of the dermal-epidermal
junction
PMN from healthy volunteers were isolated as previously described
(Sitaru et al., 2002b). Separation of the dermal-epidermal junction of
cryosections of human skin was evaluated using an ex vivo model as
previously described (Sitaru et al., 2002a; Sitaru et al., 2002b).
Finally, separation of the dermal-epidermal junction in the absence
or presence of PDE4 inhibitors (preincubation with PMN for 15
minutes at room temperature) was calculated as length of separation
divided by total length of the dermal-epidermal junction measured
with BZ-9000 fluorescence microscope (Keyence, Frankfurt,www.jidonline.org 2217
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2218Germany). Evaluation was carried out by an investigator unaware of
the section’s treatments. Each compound was tested with PMN from
four healthy donors.
Determination of CD62L, CD11b, and CD66b expression
PMN by flow cytometry
Granulocytes from healthy adult volunteers (n ¼ 8) were isolated as
previously described (Aga et al., 2002; Laufs et al., 2002; Lotz et al.,
2004). All procedures were conducted at room temperature. After
preincubation with or without the presence of each PDE4 inhibitor
at various concentrations for 15 minutes, PMN were applied to an
IC-coated 96-well plate (prepared as described above) and incu-
bated for 1 hour at 37 C. Cells were stained using anti-human
CD66b-FITC (BD, Heidelberg, Germany), anti-human CD62L-APC
(BioLegend, München, Germany) and anti-human CD11b-R PE
(Caltag, Hamburg, Germany). Samples were analyzed on a BD
FACSCalibur flow cytometer (BD Biosciences, San Jose, CA), and the
data were evaluated using Cell Quest Pro (BD Biosciences).
Murine EBA models
For antibody transfer-induced EBA, C57BL/6J mice were subcuta-
neously injected with 2 mg of total rabbit IgG collected from rabbits
immunized with murine vWFA2 (injections on experimental days 0,
2, 4, 6, 8, and 10). Administration of vehicle (0.5% carboxymethyl
cellulose, 0,25% Tween 80), 1 mg/kg of ROF, or 5 mg/kg of ROF
once daily by oral gavage was started on the day before the first IgG
injection (day e1) and continued until day 11; 20 mg/kg of meth-
ylprednisolone (Urbason, Sanofi-Aventis, Frankfurt, Germany) in
0.9% NaCl was administrated intraperitoneally once daily. On day
12, serum and organs were obtained for analysis of secondary
endpoints. For induction of immunization-induced EBA, B6.SJL-H2s
mice were immunized via the hind footpad with 120 mg recombi-
nant protein of murine vWFA2 domain emulsified in the nonionic
block copolymer adjuvant TiterMax (ALEXIS Biochemicals, Nor-
cross, GA). Thereafter, the mice were evaluated weekly for the
presence of skin lesions. If an individual mouse had 2% or more of
its body surface area affected, it was randomly allocated to treatment
with vehicle (0.5% CMC, 0.25% Tween 80) or 5 mg/kg of ROF once
daily by oral gavage. Disease severity was calculated as percentage
of body surface area affected by skin lesions (i.e., erosions, crusts,
and/or erythema), and total clinical disease severity during the
observation period was expressed as area under the curve calculated
from the disease manifestations over time for each individual mouse.
After allocation to treatment, serum samples were collected every
week in immunization-induced EBA. Ear skin samples were ob-
tained at the final day and analyzed by histopathology. Peripheral
blood cells taken from the immunization-induced mouse model (n ¼
5 from each group) on the final day were counted using a Hemavet
950FS (Drew Scientific, Oxford, CT). Serum samples from the
immunization-induced mouse model (0e6 weeks of treatment,
n ¼ 6 from each group) were analyzed for the concentration of anti-
vWFA2 IgG by ELISA as previously described (Iwata et al., 2013).
Statistical analysis
The data are presented as the mean  standard error of the mean.
Statistical calculations were performed using SigmaPlot version 12.0
(Systat Software, San Jose, CA). The tests used are indicated in the
figure legends. A P-value of 0.05 was considered to be statistically
significant.
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